US2577978A - Diagnostic composition - Google Patents
Diagnostic composition Download PDFInfo
- Publication number
- US2577978A US2577978A US74706A US7470649A US2577978A US 2577978 A US2577978 A US 2577978A US 74706 A US74706 A US 74706A US 7470649 A US7470649 A US 7470649A US 2577978 A US2577978 A US 2577978A
- Authority
- US
- United States
- Prior art keywords
- acetone
- bodies
- urine
- nitroprusside
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 103
- 210000002700 urine Anatomy 0.000 claims description 21
- -1 ALKALI METAL SALT Chemical class 0.000 claims description 16
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 229960002460 nitroprusside Drugs 0.000 claims description 15
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 15
- 239000008101 lactose Substances 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 9
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 244000178870 Lavandula angustifolia Species 0.000 description 8
- 239000001102 lavandula vera Substances 0.000 description 8
- 235000018219 lavender Nutrition 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 235000019800 disodium phosphate Nutrition 0.000 description 6
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 6
- 229940083618 sodium nitroprusside Drugs 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- OKUKPTPBWZBYSX-UHFFFAOYSA-N dipotassium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N OKUKPTPBWZBYSX-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 244000041506 Lavandula officinalis Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 101710070533 Testin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002696 acid base indicator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940029258 sodium glycinate Drugs 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
Definitions
- the present invention relates to new and improved diagnostic compositions useful for the qualitative detection and quantitative estimation of ketone bodies in body fluids, particularly acetone bodies in the urine.
- the invention relates to diagnostic compositions in solid dry form, preferably tableted in suitable sized tablets, which composition can readily be used, even by unskilled persons, rapidly to detect the presence of acetone in urine without evolvement of ammonia, with ready distinction between positive and negative tests, and without the use of equipment or apparatus other than some means of obtaining a drop of test fluid.
- acetone bodies or ketone bodies are regarded as normal intermediate compounds which are subsequently oxidized to carbon dioxide and water.
- the ketone bodies include acetone, acetoacetic acid (beta-ketchutyric acid or diacetic acid) and beta-hydroxybutyric acid.
- acetone bodies include acetone, acetoacetic acid (beta-ketchutyric acid or diacetic acid) and beta-hydroxybutyric acid.
- beta-hydroxybutyric acid beta-hydroxybutyric acid
- reagents and techniques have been used or proposed in the past for the detection of acetone bodies in urine.
- a number of such reagents and technicues have involved the use of a water soluble nitroprusside as a reactive ingredient or agent.
- the nitroprusside reaction is carried out in the presence of ammonia in order to develop particu ar colorations (see United States Patent No. 2.186902 to Fortune).
- An improvement over the Fortune tvpe formulation is disclosed in copending application Serial No. 12.699, filed March 2, 1948, now Patent No. 2509,140 issued on May 23, 1950. by Alfred H. Free, assigned to the assi nee of t e present application.
- Application Serial No. 12.699 discloses formulations for detection of acetone bo ies in the urine which contain water soluble nitroprusside, an aliphatic amino acid and an alkaline material.
- the object of the present invention is the provision of improved diagnostic compositions in stable dry form, preferably as tablets, which can be used even by an unskilled person conveniently to give an accurate quali-- tative test for, and a quantitative estimation of. the presence of acetone bodies in urine, which test clearly distinguishes between positive and negative specimens, even when the quantity of acetone is small, so as to give only what is known as a trace positive.
- An important object of the invention is the provision of a stable dry diagnostic composition for the detection of acetone bodies in urine which contains a water-soluble nitroprusside, an aliphatic amino acid, and an alkaline material, as active in redients, and in addition contains lactose which serves to prevent color change in the case of acetone-negatives and to keep the colors in the whole range of positives very truly and characteristically lavender, so that there will be no chance for confusion between positive and negative specimens, even where there are only trace amounts of acetone bodies in the positives.
- Example I The following formulation is uniformly composed by known blending and mixing techniques,
- a drop of the urine specimen to be tested is dropped onto a tablet made from the above formulation. If the specimen contains acetone bodies, a characteristic and definite lavender coloration is quickly produced which is highly characteristic and specific to acetone positive specimens. Trace positives (i. e. positive specimens with only a trace amount of acetone bodies), will also give this characteristic lavender coloration.
- the depth of the shade or hue of the lavender coloration can be used as a basis for estimating quantitatively the amount of acetone bodies present in the specimen.
- a color chart may be supplied which is graduated into different shades or hues of lavender corresponding to known concentrations of acetone bodies.
- lactose containing tablets result in the production of a stable cream color when negative specimens are applied thereto, but in the case of positive reactions a true lavender color is obtained which remains constant for 15 to 30 minutes or more, after the maximum color intensity is reached.
- an important advantage of a lactose-containing composition, as hereinbefore described lies in the fact that the time within which a test must be read is substantially extended. Furthermore, since the hue of the final color is stable, the use of a color chart is made much less difficult and more accurate than heretobefore.
- Example 2 By omitting the sodium borate, corn starch and magnesium stearate from the formulation in Example 1, a dry powder formulation may be prepared which, as such, issuitable for use in the detection of acetone bodies in urine. However, it is not adapted to be tableted.
- Example 1 is the presently preferred one for the preparation of reaction test tablets, and the formulation set forth in Example 2 is the p2 ferred one for reaction test powder, it will be understood that those skilled in the art will be able to prepare a large number of other specific formulations embodying our present invention, but which may be somewhat different in respect to specific proportions than the formulations set forth in Examples 1 and 2.
- the reactive ingredients may be considered to be the water-soluble nitroprusside, and the aliphatic amino acid.
- sodium nitroprusside is the preferred soluble nitroprusside and glycine is the preferred aliphatic amino acid.
- all of the alkali metal nitroprussides are water soluble, and any one of them may be used such, for example, as the potassium nitroprusside.
- potassium nitroprusside in a molecularly equivalent amount may be substituted for the sodium nitroprusside in Examples 1 and 2.
- the glycine may be replaced with another aliphatic amino acid such as alanine, glutamic acid, arginine, aspartic acid and lysine.
- alkaline material which is necessary in order to have the test reaction carried out under alkaline conditions.
- any alkaline material which will produce this result may be used, it of course being necessary that the alkaline material be one that permits the preparation and storage of a stable diagnositic composition, which does not interfere with the test reaction, and which is not reactive with either the glycine or the soluble nitroprusside.
- anhydrous disodium phosphate is the preferred alkaline material for use in our reagent test compositions
- other dry alkaline solids which may be used include, the alkalimetal carbonates and hydroxides, trisodium phosphate, dipotassium phosphate, and the like.
- the alkaline material may be provided in combination with the aliphatic amino acid.
- the alkali metal salts of the amino acids such as potassium or sodium glycinate, may be used both for providing the amino acid and for providing the alkalinity.
- lactose The other essential ingredient for our preferred test reagent composition is lactose.
- Other stabilizing materials such as sucrose or dextrose may be used; however, we have found that gen erally they are not as desirable as lactose be cause they appear to have an inhibiting effect on color formation. That is to say, while these less desirable materials may prevent the negatives from turning gold and the positives from turning brown, the intensity of the lavender i reduced.
- diluents may be added as desired, in order to ob-, tain better tableting properties, improved color (i. e. whiteness), improved free-flowin properties, etc.
- this ingredient should not comprise over approximately 5% of the total bulk of the mixture and should represent at least 0.04% by Weight of the total bulk.
- the preferred range of concentration for this ingredient is from 0.5 to 1
- Other soluble nitroprussides are preferably used in molecularly equivalent concentration.
- the relative proportions of disodium phosphates and glycine or their equivalents as indicated above, in the reagent compositions can vary quite Widely and still the reagent compositions will give satisfactory results with both acetone positive and acetone negative specimens. For instance, mixtures where the amount of glycine was about half that of the disodium phosphate gave clear cut tests. On the other hand, good tests were also obtained when the amount of glycine was only 1% of that of the disodium phosphate.
- the concentration of the lactose is not particularly critical. Enough of the lactose should be used so that the beneficial results contributed by it are fully obtained. On the other hand, if too much lactose is employed, there will be a tendency to slow the reaction somewhat. Desirably, enough lactose is used in any particular formulation to obtain the advantages contributed by it While not using enough appreciably to slow the test reaction.
- a diagnostic composition in solid dry form for detecting acetone bodies in urine comprising from 0.04 to 5.0% of an alkali metal nitroprus- 8.
- a diagnostic composition for detecting acetone bodies in urine comprising from 0.04 to 5.0% of a water-soluble nitroprusside, an aliphatic amino acid, an alkaline material, and a sugar selected from the group consisting of lactose, dextrose and sucrose.
- a diagnostic composition in solid dry form for detecting acetone bodies in urine comprising by weight, from 0.04-5.0% of sodium nitroprusside, from 1-20% of glycine, from 20-80% of disodium phosphate, and from 5 to 25% of lactose.
- a diagnostic composition in solid dry form for detecdng acetone bodies in urine comprising by weight, approximately 4.5 parts of glycine, approximately 0.5 part of sodium nitroprusside, approximately 47 parts of anhydrous disodium phosphate, and approximately 10 parts of lactose.
- composition of claim 5 containing in addition, approximately 36.5 parts of sodium borate, approximately 1.25 parts of corn starch, and approximately 0.25 parts of magnesium stearate.
- a diagnostic composition for detecting acetone bodies in urine comprising from 0.04 to 5.0% of a water-soluble nitroprusside, lactose and a component selected from the group consisting of (a) a mixture of an alkaline material and an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid.
- a diagnostic composition for detecting acetone bodies in urine comprising from 0.04 to 5.0% of a water-soluble nitroprusside, a member of the group consisting of (a) an alkaline material plus an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid, and a sugar in quantity sufficient to enhance the stability of color developed by said composition in the presence of acetone bodies.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Patented Dec. 11, 1951 l'i'ED STTES ATENT FFICE DIAGNOSTIC COMPOSITION No Drawing. Application February 4, 1949, Serial No. 74,706
9 Claims.
The present invention relates to new and improved diagnostic compositions useful for the qualitative detection and quantitative estimation of ketone bodies in body fluids, particularly acetone bodies in the urine.
More specifically, the invention relates to diagnostic compositions in solid dry form, preferably tableted in suitable sized tablets, which composition can readily be used, even by unskilled persons, rapidly to detect the presence of acetone in urine without evolvement of ammonia, with ready distinction between positive and negative tests, and without the use of equipment or apparatus other than some means of obtaining a drop of test fluid.
In the metabolism of fat, acetone bodies or ketone bodies are regarded as normal intermediate compounds which are subsequently oxidized to carbon dioxide and water. The ketone bodies include acetone, acetoacetic acid (beta-ketchutyric acid or diacetic acid) and beta-hydroxybutyric acid. Under normal circumstances, no significant ouantity of these ketone substances appears in the urine. However, if there is an excessive metabolism of fat, the intermediate acetone bodies accumulate in the blood and are excreted in the urine in variable amounts. In diabetes mellitus such an excessive fat metabolism occurs and many of the symptoms of this disease can be ascribed to the toxic effects of the acetone bodies. The medical profession is well aware of the usefulness in diagnosis of tests for acetone bodies in the urine in diabetes mellitus cases. Acetone bodies also occur in the urine in other well recognized disturbances of the metabolism, and in such cases it is also important to carry out tests for detection of these substances.
A variety of reagents and techniques have been used or proposed in the past for the detection of acetone bodies in urine. A number of such reagents and technicues have involved the use of a water soluble nitroprusside as a reactive ingredient or agent. In one particular reagent formulation, the nitroprusside reaction is carried out in the presence of ammonia in order to develop particu ar colorations (see United States Patent No. 2.186902 to Fortune). An improvement over the Fortune tvpe formulation is disclosed in copending application Serial No. 12.699, filed March 2, 1948, now Patent No. 2509,140 issued on May 23, 1950. by Alfred H. Free, assigned to the assi nee of t e present application. Application Serial No. 12.699 discloses formulations for detection of acetone bo ies in the urine which contain water soluble nitroprusside, an aliphatic amino acid and an alkaline material.
2 It was found, according to application Serial No. 12,699, that when the soluble nitroprusside is present in alkaline solution with an aliphatic amino acid (e. g. glycine), a diagnostic composition is provided which is particularly adapted for the detection of acetone bodies in urine without evolvement of ammonia.
According to the present invention, it has been discovered that the addition of lactose to the diagnostic formulation set forth in application Serial No. 12,699 greatly enhances the usefulness and reliability of that type of diagnostic formulation.
The object of the present invention, generally stated, is the provision of improved diagnostic compositions in stable dry form, preferably as tablets, which can be used even by an unskilled person conveniently to give an accurate quali-- tative test for, and a quantitative estimation of. the presence of acetone bodies in urine, which test clearly distinguishes between positive and negative specimens, even when the quantity of acetone is small, so as to give only what is known as a trace positive.
An important object of the invention is the provision of a stable dry diagnostic composition for the detection of acetone bodies in urine which contains a water-soluble nitroprusside, an aliphatic amino acid, and an alkaline material, as active in redients, and in addition contains lactose which serves to prevent color change in the case of acetone-negatives and to keep the colors in the whole range of positives very truly and characteristically lavender, so that there will be no chance for confusion between positive and negative specimens, even where there are only trace amounts of acetone bodies in the positives.
Other obiectsof the invention will in part be obvious and will in part appear hereinafter.
The following example discloses a presently preferred embodiment of the invention.
Example I The following formulation is uniformly composed by known blending and mixing techniques,
In use, a drop of the urine specimen to be tested is dropped onto a tablet made from the above formulation. If the specimen contains acetone bodies, a characteristic and definite lavender coloration is quickly produced which is highly characteristic and specific to acetone positive specimens. Trace positives (i. e. positive specimens with only a trace amount of acetone bodies), will also give this characteristic lavender coloration.
The depth of the shade or hue of the lavender coloration can be used as a basis for estimating quantitatively the amount of acetone bodies present in the specimen. Thus, a color chart may be supplied which is graduated into different shades or hues of lavender corresponding to known concentrations of acetone bodies. By using such a chart in connection with the testin of a specimen, not only can a determination be made as to whether or not a specimen is negative or positive, but further, positive specimens can be compared with the standard color chart to obtain a fairly accurate estimation of the quantity of acetone bodies present.
The application of a negative specimen to a lactose-free test tablet or composition causes the tablet, or composition, to take on a gold coloration which progressively changes a brown shade as time passes. A po itive specimen applied to a lactose-free test tablet produces a lavender coloration which, with the passage of time becomes muddied with brown.
Not only do the lactose containing tablets result in the production of a stable cream color when negative specimens are applied thereto, but in the case of positive reactions a true lavender color is obtained which remains constant for 15 to 30 minutes or more, after the maximum color intensity is reached. Thus an important advantage of a lactose-containing composition, as hereinbefore described, lies in the fact that the time within which a test must be read is substantially extended. Furthermore, since the hue of the final color is stable, the use of a color chart is made much less difficult and more accurate than heretobefore.
The fact that no color changes are obtained with negative specimens when the formulations of the present invention are used is an important feature of particular significance in litigation cases where the reliability of an acetone test is brou ht under close scrutiny. Obviously, the reliability and probative value of any test procedure is greatly enhanced if it can be unequivocally testified that no coloration is obtained with a ne ative specimen on the one hand, whereas all positive specimens give a characteristic lavender coloration on the other hand. Such testimony is much more forceful and influential than testimony in which it would be necessary to state that coloration is obtained even with negative specimens, but such coloration is different from that obtained with positive specimens.
Example 2 By omitting the sodium borate, corn starch and magnesium stearate from the formulation in Example 1, a dry powder formulation may be prepared which, as such, issuitable for use in the detection of acetone bodies in urine. However, it is not adapted to be tableted.
Although the formulation set forth in Example 1 is the presently preferred one for the preparation of reaction test tablets, and the formulation set forth in Example 2 is the p2 ferred one for reaction test powder, it will be understood that those skilled in the art will be able to prepare a large number of other specific formulations embodying our present invention, but which may be somewhat different in respect to specific proportions than the formulations set forth in Examples 1 and 2.
In our formulations, the reactive ingredients may be considered to be the water-soluble nitroprusside, and the aliphatic amino acid. For practical purposes and availability, sodium nitroprusside is the preferred soluble nitroprusside and glycine is the preferred aliphatic amino acid. However, all of the alkali metal nitroprussides are water soluble, and any one of them may be used such, for example, as the potassium nitroprusside. Thus, potassium nitroprusside in a molecularly equivalent amount may be substituted for the sodium nitroprusside in Examples 1 and 2. The glycine may be replaced with another aliphatic amino acid such as alanine, glutamic acid, arginine, aspartic acid and lysine.
In addition to the amino acid and the watersoluble nitroprusside, two other ingredients are essential in our formulations. One is an alkaline material which is necessary in order to have the test reaction carried out under alkaline conditions. Generally, any alkaline material which will produce this result may be used, it of course being necessary that the alkaline material be one that permits the preparation and storage of a stable diagnositic composition, which does not interfere with the test reaction, and which is not reactive with either the glycine or the soluble nitroprusside. Although anhydrous disodium phosphate is the preferred alkaline material for use in our reagent test compositions, other dry alkaline solids which may be used include, the alkalimetal carbonates and hydroxides, trisodium phosphate, dipotassium phosphate, and the like. Instead of using a single alkaline ingredient, it is possible to use a mixture of the ingredients, or the alkaline material may be provided in combination with the aliphatic amino acid. For example, the alkali metal salts of the amino acids, such as potassium or sodium glycinate, may be used both for providing the amino acid and for providing the alkalinity.
The other essential ingredient for our preferred test reagent composition is lactose. Other stabilizing materials such as sucrose or dextrose may be used; however, we have found that gen erally they are not as desirable as lactose be cause they appear to have an inhibiting effect on color formation. That is to say, while these less desirable materials may prevent the negatives from turning gold and the positives from turning brown, the intensity of the lavender i reduced.
In addition to the four essential ingredients. diluents may be added as desired, in order to ob-, tain better tableting properties, improved color (i. e. whiteness), improved free-flowin properties, etc.
The exact proportions of the amino acid, soluble nitroprusside, alkaline material and lactose, are not-particularly critical within broad limits, and the ingredients may be employed in a rather wide range of proportions. However, as the pro portions of the ingredients in the diagnostic formulations are varied, it has been noted that the properties of the formulaiions are altered in one or more of the following respects:
1. The speed of reaction of the reagent composition with acetone pos t ve urines.
2. The sensitivity of the reagent detecting small quantities of acelone bodies.
3. The stability of the reagent formulations when stored under adverse enviromnental conditions.
When sodium nitroprusside is used as the water soluble nitroprusside in our diagnostic compositions, this ingredient should not comprise over approximately 5% of the total bulk of the mixture and should represent at least 0.04% by Weight of the total bulk. The preferred range of concentration for this ingredient is from 0.5 to 1 Other soluble nitroprussides are preferably used in molecularly equivalent concentration.
The relative proportions of disodium phosphates and glycine or their equivalents as indicated above, in the reagent compositions can vary quite Widely and still the reagent compositions will give satisfactory results with both acetone positive and acetone negative specimens. For instance, mixtures where the amount of glycine was about half that of the disodium phosphate gave clear cut tests. On the other hand, good tests were also obtained when the amount of glycine was only 1% of that of the disodium phosphate.
The concentration of the lactose is not particularly critical. Enough of the lactose should be used so that the beneficial results contributed by it are fully obtained. On the other hand, if too much lactose is employed, there will be a tendency to slow the reaction somewhat. Desirably, enough lactose is used in any particular formulation to obtain the advantages contributed by it While not using enough appreciably to slow the test reaction.
In general the optimum ranges of concentration of the four preferred ingredients are as follows:
Percent by weight When diluents or other inactive ingredients are employed, they do not serve to affect the above preferred concentrations of the required components except that the sodium nitroprusside or its equivalent should represent at least 0.04% by weight of the total bulk. It will of course be understood that in any formulation equivalent components or ingredients may be substituted in equivalent concentrations, as pointed out above.
Having thus fully described our invention and set forth formulations representing the preferred embodiments thereof, what is claimed as new is:
1. A diagnostic composition in solid dry form for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of an alkali metal nitroprus- 8. A diagnostic composition for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of a water-soluble nitroprusside, an aliphatic amino acid, an alkaline material, and a sugar selected from the group consisting of lactose, dextrose and sucrose.
4. A diagnostic composition in solid dry form for detecting acetone bodies in urine, comprising by weight, from 0.04-5.0% of sodium nitroprusside, from 1-20% of glycine, from 20-80% of disodium phosphate, and from 5 to 25% of lactose.
5. A diagnostic composition in solid dry form for detecdng acetone bodies in urine, comprising by weight, approximately 4.5 parts of glycine, approximately 0.5 part of sodium nitroprusside, approximately 47 parts of anhydrous disodium phosphate, and approximately 10 parts of lactose.
6. The composition of claim 5 containing in addition, approximately 36.5 parts of sodium borate, approximately 1.25 parts of corn starch, and approximately 0.25 parts of magnesium stearate.
7. Diagnostic tablets tableted from the composition called for in claim 4.
8. A diagnostic composition for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of a water-soluble nitroprusside, lactose and a component selected from the group consisting of (a) a mixture of an alkaline material and an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid.
9. A diagnostic composition for detecting acetone bodies in urine comprising from 0.04 to 5.0% of a water-soluble nitroprusside, a member of the group consisting of (a) an alkaline material plus an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid, and a sugar in quantity sufficient to enhance the stability of color developed by said composition in the presence of acetone bodies.
RICHARD S. N ICHOLLS. DALE E. FONNER.
REFERENCES CITED The following references are of record in the file of this patent:
UNITED STATES PATENTS Number Name Date 2,171,962 Fortune Sept. 5, 1939 2,186,902 Fortune Jan. 9, 1940 2,283,262 Kamlet May 19, 1942 2,362,478 Galat Nov. 14, 1944 2,509,140 Free May 23, 1950 OTHER REFERENCES Gregory: Uses and Applications of Chemicals and Related Materials, vol. I, Reinhold Pub. Co., N. Y. 0., 1939, pg. 112, col. 2.
Kolthofi et al.: Acid Base Indicators, MacMillian 00., N. Y. 0., 1937, pgs. 247-252 (Inc.).
Claims (1)
- 9. A DIAGNOSTIC COMPOSITION FOR DETECTING ACETONE BODIES IN URINE COMPRISING FROM 0.04 TO 5.0% OF A WATER-SOLUBLE NITROPRUSSIDE, A MEMBER OF THE GROUP CONSISTING OF (A) AND ALKALINE MATERIAL PLUS AN ALIPHATIC AMINO ACID AND (B) AN ALKALINE ALKALI METAL SALT OF AN ALIPHATIC AMINO ACID, AND A SUGAR IN QUANTITY SUFFICIENT TO ENHANCE THE STABILITY OF COLOR DEVELOPED BY SAID COMPOSITION IN THE PRESENCE OF ACETONE BODIES.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74706A US2577978A (en) | 1949-02-04 | 1949-02-04 | Diagnostic composition |
GB1881/50A GB667715A (en) | 1949-02-04 | 1950-01-24 | Improvements in or relating to diagnostic compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74706A US2577978A (en) | 1949-02-04 | 1949-02-04 | Diagnostic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US2577978A true US2577978A (en) | 1951-12-11 |
Family
ID=22121173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US74706A Expired - Lifetime US2577978A (en) | 1949-02-04 | 1949-02-04 | Diagnostic composition |
Country Status (2)
Country | Link |
---|---|
US (1) | US2577978A (en) |
GB (1) | GB667715A (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2737501A (en) * | 1954-10-06 | 1956-03-06 | Cambridge Chemical Products Co | Diagnostic preparation for the determination of serum bilirubin |
US2824842A (en) * | 1954-06-09 | 1958-02-25 | Sulkowitch Hirsh | Urine calcium test |
US2990253A (en) * | 1959-05-21 | 1961-06-27 | Miles Lab | Diagnostic composition |
US3005794A (en) * | 1958-08-08 | 1961-10-24 | Francis R Shonka | Method of using and manufacturing plastic equivalent to organic materials |
US3048475A (en) * | 1958-06-16 | 1962-08-07 | Miles Lab | Method and diagnostic composition of detecting phenylketones |
DE1153920B (en) * | 1957-10-21 | 1963-09-05 | Miles Lab | Diagnostic agent for the determination of ketone compounds in body fluids |
US3212855A (en) * | 1962-08-06 | 1965-10-19 | Miles Lab | Diagnostic device |
US3880590A (en) * | 1973-11-08 | 1975-04-29 | Shionogi & Co | Test strip for ketone bodies |
FR2390733A1 (en) * | 1977-05-13 | 1978-12-08 | Behringwerke Ag | CONTROL SOLUTION FOR DETECTION FOR DIAGNOSIS OF SUBSTANCES CONTAINED IN URINE |
US4147514A (en) * | 1977-11-21 | 1979-04-03 | Miles Laboratories, Inc. | Test means and method for detecting ketone bodies |
US4405721A (en) * | 1980-03-22 | 1983-09-20 | Behringwerke Aktiengesellschaft | Diagnostic agent for the detection of ketone bodies |
US4970172A (en) * | 1986-12-22 | 1990-11-13 | Abbott Laboratories | Method and device for ketone measurements |
US5071769A (en) * | 1986-12-22 | 1991-12-10 | Abbott Laboratories | Method and device for ketone measurement |
US6583722B2 (en) | 2000-12-12 | 2003-06-24 | Kimberly-Clark Worldwide, Inc. | Wetness signaling device |
US6603403B2 (en) | 2000-12-12 | 2003-08-05 | Kimberly-Clark Worldwide, Inc. | Remote, wetness signaling system |
WO2012122394A1 (en) * | 2011-03-08 | 2012-09-13 | Akers Biosciences, Inc. | Breath ketone detector |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3020568C2 (en) * | 1980-05-30 | 1983-01-20 | Peter Dr. 6719 Altleiningen Rieckmann | Process for the analytical determination of the constituents of body fluids as well as solid carriers and devices for carrying out the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2171962A (en) * | 1938-12-19 | 1939-09-05 | Lilly Co Eli | Urine albumin test |
US2186902A (en) * | 1939-04-07 | 1940-01-09 | Lilly Co Eli | Urine acetone test |
US2283262A (en) * | 1940-10-02 | 1942-05-19 | Miles Lab | Diagnostic composition and method |
US2362478A (en) * | 1941-12-24 | 1944-11-14 | Denver Chemical Mfg Company | Reagent for testing for acetone |
US2509140A (en) * | 1948-03-02 | 1950-05-23 | Miles Lab | Test reagent composition |
-
1949
- 1949-02-04 US US74706A patent/US2577978A/en not_active Expired - Lifetime
-
1950
- 1950-01-24 GB GB1881/50A patent/GB667715A/en not_active Expired
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2171962A (en) * | 1938-12-19 | 1939-09-05 | Lilly Co Eli | Urine albumin test |
US2186902A (en) * | 1939-04-07 | 1940-01-09 | Lilly Co Eli | Urine acetone test |
US2283262A (en) * | 1940-10-02 | 1942-05-19 | Miles Lab | Diagnostic composition and method |
US2362478A (en) * | 1941-12-24 | 1944-11-14 | Denver Chemical Mfg Company | Reagent for testing for acetone |
US2509140A (en) * | 1948-03-02 | 1950-05-23 | Miles Lab | Test reagent composition |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2824842A (en) * | 1954-06-09 | 1958-02-25 | Sulkowitch Hirsh | Urine calcium test |
US2737501A (en) * | 1954-10-06 | 1956-03-06 | Cambridge Chemical Products Co | Diagnostic preparation for the determination of serum bilirubin |
DE1153920B (en) * | 1957-10-21 | 1963-09-05 | Miles Lab | Diagnostic agent for the determination of ketone compounds in body fluids |
US3048475A (en) * | 1958-06-16 | 1962-08-07 | Miles Lab | Method and diagnostic composition of detecting phenylketones |
US3005794A (en) * | 1958-08-08 | 1961-10-24 | Francis R Shonka | Method of using and manufacturing plastic equivalent to organic materials |
US2990253A (en) * | 1959-05-21 | 1961-06-27 | Miles Lab | Diagnostic composition |
US3212855A (en) * | 1962-08-06 | 1965-10-19 | Miles Lab | Diagnostic device |
US3880590A (en) * | 1973-11-08 | 1975-04-29 | Shionogi & Co | Test strip for ketone bodies |
FR2390733A1 (en) * | 1977-05-13 | 1978-12-08 | Behringwerke Ag | CONTROL SOLUTION FOR DETECTION FOR DIAGNOSIS OF SUBSTANCES CONTAINED IN URINE |
US4172049A (en) * | 1977-05-13 | 1979-10-23 | Behringwerke Aktiengesellschaft | Control-solution for diagnostic detection methods for substances contained in the urine |
US4147514A (en) * | 1977-11-21 | 1979-04-03 | Miles Laboratories, Inc. | Test means and method for detecting ketone bodies |
US4405721A (en) * | 1980-03-22 | 1983-09-20 | Behringwerke Aktiengesellschaft | Diagnostic agent for the detection of ketone bodies |
US4970172A (en) * | 1986-12-22 | 1990-11-13 | Abbott Laboratories | Method and device for ketone measurements |
US5071769A (en) * | 1986-12-22 | 1991-12-10 | Abbott Laboratories | Method and device for ketone measurement |
US6583722B2 (en) | 2000-12-12 | 2003-06-24 | Kimberly-Clark Worldwide, Inc. | Wetness signaling device |
US6603403B2 (en) | 2000-12-12 | 2003-08-05 | Kimberly-Clark Worldwide, Inc. | Remote, wetness signaling system |
WO2012122394A1 (en) * | 2011-03-08 | 2012-09-13 | Akers Biosciences, Inc. | Breath ketone detector |
JP2014509732A (en) * | 2011-03-08 | 2014-04-21 | エイカーズ バイオサイエンシス インコーポレイテッド | Breath ketone detector |
US8871521B2 (en) | 2011-03-08 | 2014-10-28 | Akers Biosciences, Inc. | Breath ketone detector |
Also Published As
Publication number | Publication date |
---|---|
GB667715A (en) | 1952-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2577978A (en) | Diagnostic composition | |
Grodsky et al. | Simplified preliminary blood testing--An improved technique and a comparative study of methods | |
Macpherson | Modified procedures for the colorimetric estimation of arginine and histidine | |
Russell | The colorimetric estimation of small amounts of ammonia by phenol: itypochlorite reaction | |
Hunter | A new test for ergothioneine upon which is based a method for its estimation in simple solution and in blood-filtrates | |
US2509140A (en) | Test reagent composition | |
US3472738A (en) | Test implement for detecting peroxidase | |
US2283262A (en) | Diagnostic composition and method | |
US3798000A (en) | Agent and method for determination of calcium | |
US3663175A (en) | Method of determining hemoglobin in blood | |
Junnosuke et al. | Serum glycylproline dipeptidyl aminopeptidase activity in human hepatic cancer | |
CA1260371A (en) | Free flowing granular indicator material for peroxidase-like activity | |
US2999052A (en) | Composition for colorimetric test for serum enzymes | |
US3461036A (en) | Test composition,device and method for detecting urea in aqueous fluids | |
Corns | Infrared analysis of renal calculi: a comparison with conventional techniques | |
EP1525471B1 (en) | Agent for detecting malondialdehyde, method of making the same, and test kit for use thereof | |
US3536448A (en) | Uric acid detection | |
US2999793A (en) | Diagnostic preparation and process for the determination of serum alkaline phosphatase | |
Campbell | The estimation of calcium and magnesium | |
Rupe et al. | An improved test for phenylketonuria | |
US3526479A (en) | Diagnostic article and method for detection therewith | |
Ratnaike et al. | Blood ammonia measurement using a simple reflectometer | |
US3310382A (en) | Biuret reagent | |
US3754862A (en) | Reagnet composition and method for determining total bilirubin | |
Bradbury | A simplified method for the estimation of sodium |